Related references
Note: Only part of the references are listed.Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
Enhancement of antibody-dependent cellular cytotoxicity of cetuximab by a chimeric protein encompassing interleukin-15
Maria Carmen Ochoa et al.
ONCOIMMUNOLOGY (2018)
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment
Anje Cauwels et al.
ONCOIMMUNOLOGY (2018)
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Rizwan Romee et al.
BLOOD (2018)
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Silvia C. Formenti et al.
CLINICAL CANCER RESEARCH (2018)
T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors
Jiemiao Hu et al.
CLINICAL CANCER RESEARCH (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase Ib trial of ALT-803, an IL-15 superagonist, plus BCG for the treatment of BCG-naive patients with non-muscle-invasive bladder cancer.
Charles Joel Rosser et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
John M. Wrangle et al.
LANCET ONCOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Karin M. Knudson et al.
ONCOIMMUNOLOGY (2018)
Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
Stacey Stein et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).
Nizar M. Tannir et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) plus chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
Adi Diab et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Jeffrey S. Miller et al.
CLINICAL CANCER RESEARCH (2018)
Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments
Anje Cauwels et al.
CANCER RESEARCH (2018)
Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model
Marcos Vasquez et al.
ONCOTARGET (2017)
IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination
Diana Llopiz et al.
ONCOTARGET (2017)
Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology
Jessica Fioravanti et al.
JOURNAL OF HEPATOLOGY (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Cergutuzumab amunaleukin (CEA-IL2v), a CEA- targeted IL-2 variant- based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Christian Klein et al.
ONCOIMMUNOLOGY (2017)
Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy
Deborah Charych et al.
PLOS ONE (2017)
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer
Charli Dominguez et al.
JCI INSIGHT (2017)
Interleukin-8 in cancer pathogenesis, treatment and follow-up
Carlos Alfaro et al.
CANCER TREATMENT REVIEWS (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
Peter R. Rhode et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
Aung Naing et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure
Marianna Di Scala et al.
ONCOTARGET (2016)
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
Claire Vanpouille-Box et al.
CANCER RESEARCH (2015)
Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Ling Zhang et al.
CLINICAL CANCER RESEARCH (2015)
IL-35 and Autoimmunity: a Comprehensive Perspective
Jinjung Choi et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2015)
TRUCKs: the fourth generation of CARs
Markus Chmielewski et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
Kevin C. Conlon et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Therapeutic potential of chemokine signal inhibition for metastatic breast cancer
Takanori Kitamura et al.
PHARMACOLOGICAL RESEARCH (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
Jose I. Quetglas et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Ignacio Melero et al.
NATURE REVIEWS CANCER (2015)
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Xuanming Yang et al.
CANCER CELL (2014)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Exploiting the curative potential of adoptive T-cell therapy for cancer
Christian S. Hinrichs et al.
IMMUNOLOGICAL REVIEWS (2014)
Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma A Randomized Clinical Trial
F. Stephen Hodi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Differential Requirement for IL-2 and IL-15 during Bifurcated Development of Thymic Regulatory T Cells
Daniel Marshall et al.
JOURNAL OF IMMUNOLOGY (2014)
Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature
Robbert M. Spaapen et al.
JOURNAL OF IMMUNOLOGY (2014)
The immunocytokine NHS-IL12 as a potential cancer therapeutic
Jonathan Fallon et al.
ONCOTARGET (2014)
Myeloid-derived cells are key targets of tumor immunotherapy
Jose Medina-Echeverz et al.
ONCOIMMUNOLOGY (2014)
Evaluation of a novel CD20-targeted IL-15 immunotherapeutic with potent activity against B cell lymphoma
Bai Liu et al.
Journal for ImmunoTherapy of Cancer (2014)
Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein
Maria C. Ochoa et al.
CANCER RESEARCH (2013)
Interleukin-15 in Gene Therapy of Cancer
Maria C. Ochoa et al.
CURRENT GENE THERAPY (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF IMMUNOTHERAPY (2013)
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck et al.
NATURE MEDICINE (2013)
High-density lipoproteins delivering interleukin-15
Maria C. Ochoa et al.
ONCOIMMUNOLOGY (2013)
Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
Marie Vincent et al.
ONCOIMMUNOLOGY (2013)
A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders
John M. Timmerman et al.
CLINICAL CANCER RESEARCH (2012)
Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease
Bin Gao
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
The Fusion Protein of IFN-α and Apolipoprotein A-I Crosses the Blood-Brain Barrier by a Saturable Transport Mechanism
Jessica Fioravanti et al.
JOURNAL OF IMMUNOLOGY (2012)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
US Food and Drug Administration Approval: Peginterferon-alfa-2b for the Adjuvant Treatment of Patients with Melanoma
Thomas M. Herndon et al.
ONCOLOGIST (2012)
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
John B. Mumm et al.
CANCER CELL (2011)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs et al.
CLINICAL CANCER RESEARCH (2011)
Anchoring Interferon Alpha to Apolipoprotein A-I Reduces Hematological Toxicity While Enhancing Immunostimulatory Properties
Jessica Fioravanti et al.
HEPATOLOGY (2011)
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Sid P. Kerkar et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells
Jose Medina-Echeverz et al.
JOURNAL OF IMMUNOLOGY (2011)
Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis
M. Rodrigo-Garzon et al.
CANCER GENE THERAPY (2010)
Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial
Henrik Schmidt et al.
CLINICAL CANCER RESEARCH (2010)
Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases
Qihong Zhao
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Pedro Berraondo et al.
CURRENT GENE THERAPY (2009)
Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Interleukin-12: Biological properties and clinical application
Michele Del Vecchio et al.
CLINICAL CANCER RESEARCH (2007)
TH1 cells control themselves by producing interleukin-10
Anne O'Garra et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Dendritic cells prime natural killer cells by trans-presenting interleukin 15
Mathias Lucas et al.
IMMUNITY (2007)
Converting IL-15 to a superagonist by binding to soluble IL-15Rα
Mark P. Rubinstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
TNF-α in cancer treatment:: Molecular insights, antitumor effects, and clinical utility
Remco van Horssen et al.
ONCOLOGIST (2006)
Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ -: Hyperagonist IL-15•IL-15Rα fusion proteins
E Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response
YQ Li et al.
JOURNAL OF IMMUNOLOGY (2005)
Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors
B Sangro et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
CA Klebanoff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature:: A novel mechanism for IL-21
C Jackaman et al.
JOURNAL OF IMMUNOLOGY (2003)
Anti-TNF-α therapies:: The next generation
MA Palladino et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-I knockout mice
L Zhao et al.
BRITISH JOURNAL OF CANCER (2002)
IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma
ML Lucas et al.
MOLECULAR THERAPY (2002)
Tumor rejection by disturbing tumor stroma cell interactions
S Ibe et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity
P Romagnani et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice
MK Kennedy et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
